AI and CRISPR technologies drive proactive health monitoring

JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, tech-integrated health monitoring. These latest articles explore how existing medical screenings can be repurposed with AI and how the world's most advanced diagnostic tools are being miniaturized for everyday use.

1. AI and mammograms: Unlocking hidden heart health data

In the new feature, "AI-Quantified Breast Arterial Calcification Can Predict Heart Disease Risk From Mammograms," JMIR correspondent Shalini Kathuria Narang discusses how artificial intelligence is being used to turn routine breast cancer screenings into a dual-purpose health check. By analyzing breast arterial calcification (BAC), an AI model can now help clinicians identify women at high risk for cardiovascular disease-often the leading cause of death in women-without requiring additional appointments or blood work.

Key insights:

• Automated risk scoring: The AI provides a precise measurement of calcium buildup; every additional millimeter squared of calcification correlates to a 1% increase in cardiovascular risk.

• Proactive care for younger women: The feature notes that this AI analysis is particularly valuable for women under 50, a group frequently overlooked by traditional heart disease screening models.

• Seamless integration: Because the data is extracted from existing mammograms, this approach offers a low-barrier, cost-effective way to close the gender gap in heart disease diagnosis.

2. CRISPR-on-a-chip: A lab-quality diagnostic in your pocket

In the second feature, "CRISPR Diagnostics, in Your Pocket," Cliff Dominy, PhD, explores the intersection of gene-editing technology and microfluidics. Known as "CRISPR-on-a-chip," this emerging technology aims to provide laboratory-grade accuracy for detecting infections and early-stage cancer markers through portable, smartphone-linked devices.

Key insights:

• Hypersensitivity: By utilizing the unique properties of CRISPR enzymes, these chips can be 10 to 100 times more sensitive than standard PCR tests.

• Single-molecule detection: The article highlights the potential of graphene-based sensors to spot a single molecule of tumor DNA in the bloodstream, long before physical symptoms appear.

• Accessibility: These devices could soon allow for high-precision testing at the patient's bedside or even at home, moving diagnostics away from bulky laboratory infrastructure.

A vision for proactive health

Together, these stories illustrate a future where healthcare is increasingly proactive. Whether it is by extracting new insights from routine imaging or putting molecular-grade testing into a pocket-sized device, these technological shifts represent a new frontier in the effort to detect and manage disease earlier than ever before.